-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Who are the Alternatives for Cellular Therapies? Engineering and Retargeting Other Effector Lymphocytes

Sponsor: Education
Program: Spotlight Sessions
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Biological therapies, Translational Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Therapies, Immunotherapy, emerging technologies, Technology and Procedures
Monday, December 11, 2023: 2:45 PM-4:00 PM
Room 11 (San Diego Convention Center)
Dean Anthony Lee, MD, PhD, ARRAY(0xfcb6098)
Lee: Avidicure B.V.: Consultancy, Current equity holder in private company, Research Funding; Kiadis Pharma, a Sanofi Corporation: Consultancy, Patents & Royalties: licensed through Nationwide Children's Hospital.
Autologous CD19-specific CAR-T cells have demonstrated remarkable activity against several B-cell malignancies, facilitating the explosion of an entirely new field of therapeutics. However, surprising failures in their development have refocused the field on solving product manufacture delays and failures, and recognizing that the biologic properties of autologous products derived from heavily-treated patients may not be optimal. Moreover, the field continues to evolve in its understanding that the ideal phenotypes and effector functions may vary among disease indications. In parallel, our understanding of the biology and progress in manufacturing has progressed rapidly for alternative effector cell types to the classic αβ T cells. These alternative types - namely γδ T cells, NKT cells, and NK cells - possess similar effector function but with distinct cytokine profiles, metabolic pathways, and homing receptor repertoires, along with low GvHD potential when administered across HLA barriers. These properties may make them ideal candidates for specific indications and make them more amenable to implementation as off-the-shelf allogeneic cellular therapeutics. Here, we will compare and contrast these alternative cell types, describe the features that make them amenable to specific indications, and present new advances in the manufacturing, genetic modification, and clinical testing for hematologic cancers.

Carlos A. Ramos, MD

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX

Jonathan P H Fisher

Cancer Section, UCL Great Ormond Street Institute of Child Health, London, ENG, United Kingdom

See more of: Spotlight Sessions